Scarica l'app Stockscreener
255.99
0.26%
-0.4406
Precedente Chiudi:
$256.43
Aprire:
$256.34
Volume 24 ore:
120.77K
Relative Volume:
0.24
Capitalizzazione di mercato:
$9.90B
Reddito:
$1.24B
Utile/perdita netta:
$42.23M
Rapporto P/E:
241.50
EPS:
1.06
Flusso di cassa netto:
$150.33M
1 W Prestazione:
+0.51%
1M Prestazione:
-4.20%
6M Prestazione:
+7.39%
1 anno Prestazione:
+42.12%
Intervallo 1D:
$254.06
$258.20
Intervallo di 1 settimana:
$250.68
$258.20
Portata 52W:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
Nome
Penumbra Inc
Settore
Industria
Telefono
(510) 995-2486
Indirizzo
ONE PENUMBRA PLACE, ALAMEDA, CA
Confronta PEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
255.93 | 9.90B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
135.79 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
107.15 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.79 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.27 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.33 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-14 | Iniziato | BofA Securities | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-12-17 | Iniziato | Oppenheimer | Outperform |
| 2024-12-11 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Iniziato | Stifel | Buy |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-31 | Downgrade | Citigroup | Buy → Neutral |
| 2024-07-31 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-29 | Downgrade | Needham | Buy → Hold |
| 2023-01-30 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-10-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-09-09 | Aggiornamento | Needham | Hold → Buy |
| 2022-07-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-04-19 | Iniziato | Deutsche Bank | Buy |
| 2022-03-08 | Iniziato | Needham | Hold |
| 2021-09-16 | Iniziato | Truist | Buy |
| 2021-06-04 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-12-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-10-07 | Ripresa | Canaccord Genuity | Buy |
| 2020-09-29 | Iniziato | BTIG Research | Buy |
| 2020-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-05-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Iniziato | William Blair | Outperform |
| 2018-10-29 | Ripresa | BofA/Merrill | Buy |
| 2018-10-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-02-21 | Iniziato | William Blair | Outperform |
| 2018-01-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Reiterato | Canaccord Genuity | Buy |
| 2015-10-13 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Penumbra Inc Borsa (PEN) Ultime notizie
Insider Selling: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus
Penumbra director O’Rourke sells $12988 in stock - Investing.com
Inquis, Penumbra advance thrombectomy treatments - BioWorld MedTech
Transcript : Penumbra, Inc. Presents at 2025 Truist Securities MedTech Conference, Jun-17-2025 10 - MarketScreener
Penumbra, Inc. Announces Completion of Enrollment for Landmark S - GuruFocus
Penumbra Completes Enrollment for STORM-PE Randomized Controlled Trial - Diagnostic and Interventional Cardiology
Penumbra completes enrollment in pulmonary embolism trial - MassDevice
Penumbra's Revolutionary PE Treatment Trial Hits 100-Patient Mark, Results Could Transform Blood Clot Care - Stock Titan
Clot Management Devices Market Set to Witness Significant - openPR.com
PEN Stock Rises Following the Launch of Ruby XL System - MSN
RSI Alert: Penumbra (PEN) Now Oversold - Nasdaq
Zacks Industry Outlook Penumbra, Integer and AngioDynamics - Yahoo Finance
Penumbra Introduces the Ruby XL System – the Longest, Largest, and Softest Coil on the Market for Vascular Embolization - HMP Global Learning Network
Insider Sell: Johanna Roberts Sells 600 Shares of Penumbra Inc (PEN) - GuruFocus
Penumbra Introduces the Ruby® XL Systemthe Longest, Largest, and Softest Coil on the Market for Vascular Embolization - StreetInsider
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Continues Penumbra (PEN) Fraud Investigation In Light Of Company’s Admissions, Encourages Investors to Contact its Attorneys Now - ACCESS Newswire
Penumbra Introduces the Ruby® Xl System - marketscreener.com
PEN Unveils Ruby XL System with FDA Clearance | PEN Stock News - GuruFocus
Penumbra Launches US FDA-Cleared Ruby XL Coil System - marketscreener.com
Penumbra announces FDA approval, launch of Ruby XL System - TipRanks
Just Launched: Penumbra's New Ruby XL System Delivers 40mm Coils Through Standard CathetersLargest in Market - Stock Titan
Penumbra’s EVP Johanna Roberts sells $154,903 in stock By Investing.com - Investing.com Canada
Penumbra’s EVP Johanna Roberts sells $154,903 in stock - Investing.com Australia
Transcript : Penumbra, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 09 - marketscreener.com
Transcript : Penumbra, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 02 - marketscreener.com
Penumbra Inc (PEN) Shares Gap Down to $257.585 on Jun 2 - GuruFocus
Penumbra Insider Sold Shares Worth $4,366,920, According to a Recent SEC Filing - marketscreener.com
3 Reasons to Sell PEN and 1 Stock to Buy Instead - Yahoo Finance
Penumbra CEO Adam Elsesser sells $4.37 million in stock By Investing.com - Investing.com India
Penumbra CEO Adam Elsesser sells $4.37 million in stock - Investing.com Australia
Penumbra Amends Incorporation Certificate After Stockholder Vote - TipRanks
Managing Acute Limb Ischemia With Penumbra Lightning Bolt™ Technology - HMP Global Learning Network
Why Investors Shouldn't Be Surprised By Penumbra, Inc.'s (NYSE:PEN) P/S - simplywall.st
Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report? - Yahoo Finance
Penumbra (NYSE:PEN) shareholders are still up 88% over 3 years despite pulling back 3.1% in the past week - Yahoo Finance
Penumbra, Inc. to Present at Upcoming Investor Conferences - Eastern Progress
Penumbra Rallies 35.9% in a Year: What's Driving the Stock? - sharewise
Penumbra, Inc. to Present at Upcoming Investor Conferences | PEN Stock News - GuruFocus
Blend Extra: Stroke Awareness Month And How Quick Action Can Save Lives - TMJ4 News
Insider Sell Alert: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus
Here's Why Penumbra (PEN) is a Strong Momentum Stock - Yahoo Finance
Penumbra EVP Johanna Roberts sells $268,697 in stock By Investing.com - Investing.com Nigeria
Penumbra Inc Azioni (PEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Penumbra Inc Azioni (PEN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Elsesser Adam | CEO and President |
Jun 25 '25 |
Option Exercise |
30.00 |
27,976 |
839,280 |
138,331 |
| Elsesser Adam | CEO and President |
Jun 25 '25 |
Sale |
253.40 |
15,890 |
4,026,589 |
122,441 |
0.19%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):